Ashley Cordova
CIK: 0001822014
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NovoCure Ltd
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Mar 4, 2026NVCR
NovoCure Ltd
Tax Payment(F)Direct17.6K shares at avg. $13.30$235K - Mar 2, 2026NVCR
NovoCure Ltd
Tax Payment(F)Direct2.4K shares at avg. $13.67$33K - Mar 2, 2026NVCR
NovoCure Ltd
Tax Payment(F)Direct7.2K shares at avg. $13.67$99K - Feb 28, 2026NVCR
NovoCure Ltd
Award(A)Direct23.8K shares- - Feb 27, 2026NVCR
NovoCure Ltd
Tax Payment(F)Direct11.5K shares at avg. $13.75$159K - Sep 5, 2025NVCR
NovoCure Ltd
Purchase(P)Direct81.6K shares at avg. $12.22$997K - Jun 30, 2025NVCR
NovoCure Ltd
Award(A)Direct833 shares at avg. $15.13$13K - Mar 4, 2025NVCR
NovoCure Ltd
Award(A)Direct151.2K shares at avg. $18.19$2.7M - Mar 3, 2025NVCR
NovoCure Ltd
Sale(S)Direct2.1K shares at avg. $18.54$38K - Feb 28, 2025NVCR
NovoCure Ltd
Sale(S)Direct2.3K shares at avg. $18.28$43K - Feb 27, 2025NVCR
NovoCure Ltd
Sale(S)Direct1.8K shares at avg. $20.55$37K - Feb 27, 2025NVCR
NovoCure Ltd
Sale(S)Direct9.3K shares at avg. $19.92$186K - Dec 31, 2024NVCR
NovoCure Ltd
Award(A)Direct373 shares at avg. $14.75$6K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 4, 2026 | NVCR NovoCure Ltd | Tax Payment(F) | 17,638 | $13.30 | $234,585 | Direct |
| Mar 2, 2026 | NVCR NovoCure Ltd | Tax Payment(F) | 2,410 | $13.67 | $32,945 | Direct |
| Mar 2, 2026 | NVCR NovoCure Ltd | Tax Payment(F) | 7,228 | $13.67 | $98,807 | Direct |
| Feb 28, 2026 | NVCR NovoCure Ltd | Award(A) | 23,818 | - | $0 | Direct |
| Feb 27, 2026 | NVCR NovoCure Ltd | Tax Payment(F) | 11,541 | $13.75 | $158,689 | Direct |
| Sep 5, 2025 | NVCR NovoCure Ltd | Purchase(P) | 81,550 | $12.22 | $996,859 | Direct |
| Jun 30, 2025 | NVCR NovoCure Ltd | Award(A) | 833 | $15.13 | $12,603 | Direct |
| Mar 4, 2025 | NVCR NovoCure Ltd | Award(A) | 151,181 | $18.19 | $2,749,982 | Direct |
| Mar 3, 2025 | NVCR NovoCure Ltd | Sale(S) | 2,053 | $18.54 | $38,055 | Direct |
| Feb 28, 2025 | NVCR NovoCure Ltd | Sale(S) | 2,341 | $18.28 | $42,804 | Direct |
| Feb 27, 2025 | NVCR NovoCure Ltd | Sale(S) | 1,808 | $20.55 | $37,153 | Direct |
| Feb 27, 2025 | NVCR NovoCure Ltd | Sale(S) | 9,345 | $19.92 | $186,170 | Direct |
| Dec 31, 2024 | NVCR NovoCure Ltd | Award(A) | 373 | $14.75 | $5,501 | Direct |
1-13 of 13 transactions
About Cordova Ashley
Cordova Ashley (SEC CIK 0001822014) files insider reports with the SEC as Former Chief Executive Officer of NovoCure Ltd (NVCR).
Signal8 holds 9 ownership filings by Cordova Ashley, all Form 4s, filed between Jan 3, 2025 and Mar 5, 2026. Those filings report 13 transactions, from Dec 31, 2024 to Mar 4, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Cordova Ashley's filings is in WAYNE, PA.
Recent filings by Cordova Ashley
- Mar 4, 2026: Tax withholding of NVCR shares (Form 4, code F).
- Mar 2, 2026: Tax withholdings of NVCR shares (2 lines, Form 4, code F).
- Feb 28, 2026: Grant or award of NVCR shares (Form 4, code A).
- Feb 27, 2026: Tax withholding of NVCR shares (Form 4, code F).
- Sep 5, 2025: Open-market purchase of NVCR shares (Form 4, code P).
Other insiders filing for NovoCure Ltd (NVCR)
- Puri Michal Nath, Chief Human Resources Officer
- Leonard Frank X, Chief Executive Officer
- Ben Arye Barak, General Counsel
- Danziger Asaf, Director
- LEUNG GABRIEL, Director
- Stafford Kristin, Director